Cargando…

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study

BACKGROUND: Conventional glucocorticoid treatment has a significant impact on liver in patients with adrenal insufficiency. Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement in anthropometric and metabolic parameters. We aimed to evaluate the eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guarnotta, Valentina, Mineo, Mariagrazia Irene, Radellini, Stefano, Pizzolanti, Giuseppe, Giordano, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713956/ https://www.ncbi.nlm.nih.gov/pubmed/31489172 http://dx.doi.org/10.1177/2042018819871169

Ejemplares similares

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency
por: Guarnotta, V, et al.
Publicado: (2019)

Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
por: Bioletto, Fabio, et al.
Publicado: (2023)

Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency
por: Gasco, V., et al.
Publicado: (2022)

Metabolic Profile in a Cohort of Young Sicilian Patients with Klinefelter's Syndrome: The Role of Irisin
por: Radellini, Stefano, et al.
Publicado: (2022)

Early Metabolic Benefits of Switching Hydrocortisone to Modified Release Hydrocortisone in Adult Adrenal Insufficiency
por: Bannon, Christopher A. M., et al.
Publicado: (2021)

Prediction of diabetes mellitus induced by steroid overtreatment in adrenal insufficiency
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Tissue Glucocorticoid Metabolism in Adrenal Insufficiency: A Prospective Study of Dual-release Hydrocortisone Therapy
por: Dineen, Rosemary A, et al.
Publicado: (2023)

Levothyroxine and insulin requirement in autoimmune polyglandular type 3 syndrome: a real-life study
por: Guarnotta, V., et al.
Publicado: (2020)

The metabolic outcomes of growth hormone treatment in children are gender specific
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency
por: Ekstrand, Elise, et al.
Publicado: (2020)

Gender-specific soluble α-klotho levels as marker of GH deficiency in children: a case–control study
por: Guarnotta, V., et al.
Publicado: (2022)

Long-term outcomes of conventional and novel steroid replacement therapy on bone health in primary adrenal insufficiency
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency
por: Nilsson, A G, et al.
Publicado: (2014)

SAT-381 Cognitive Function and Quality of Sleep in Patients with Adrenal Insufficiency May Benefit by Therapy with Dual-Release Hydrocortisone
por: Krekeler, Clarissa, et al.
Publicado: (2019)

A Prospective Cross-Over Study of Tissue Glucocorticoid Metabolism in Patients With Adrenal Insufficiency: The Effects of Dual-Release Hydrocortisone Therapy
por: Dineen, Rosemary Anne, et al.
Publicado: (2021)

Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing’s syndrome, acromegaly and neuroendocrine tumours
por: Guarnotta, Valentina, et al.
Publicado: (2023)

Effects of the therapy shift from cortisone acetate to modified-release hydrocortisone in a group of patients with adrenal insufficiency
por: Frigerio, Sofia, et al.
Publicado: (2023)

Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients
por: Delle Cese, Francesca, et al.
Publicado: (2021)

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
por: Merke, Deborah P, et al.
Publicado: (2021)

Maternal-foetal complications in pregnancy: a retrospective comparison between type 1 and type 2 diabetes mellitus
por: Guarnotta, Valentina, et al.
Publicado: (2021)

Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)

One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021)

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study
por: Nilsson, Anna G, et al.
Publicado: (2017)

Improved salivary cortisol rhythm with dual-release hydrocortisone
por: Ceccato, Filippo, et al.
Publicado: (2018)

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Circulating Irisin Levels as a Marker of Osteosarcopenic-Obesity in Cushing’s Disease
por: Guarnotta, Valentina, et al.
Publicado: (2020)

Irisin: A Possible Marker of Adipose Tissue Dysfunction in Obesity
por: Tomasello, Laura, et al.
Publicado: (2023)

Exenatide Alters Absorption of Hydrocortisone in a Diabetic Patient With Panhypopituitarism: Iatrogenic Adrenal Insufficiency
por: Fujita, Yukari, et al.
Publicado: (2013)

Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency
por: Quinkler, Marcus, et al.
Publicado: (2016)

More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Hydrocortisone malabsorption due to polyethylene glycols (Macrogol 3350) in a girl with congenital adrenal insufficiency
por: Stagi, Stefano, et al.
Publicado: (2014)

Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: a retrospective analysis
por: Guarnotta, Valentina, et al.
Publicado: (2018)

Predictive factors of polycystic ovary syndrome in girls with precocious pubarche
por: Guarnotta, Valentina, et al.
Publicado: (2021)

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
por: Ciresi, A., et al.
Publicado: (2018)

Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone—Results from a randomized controlled trial
por: Werumeus Buning, Jorien, et al.
Publicado: (2017)

SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
por: Simeoli, Chiara, et al.
Publicado: (2019)

In Vitro Evaluation of Cocoa Pod Husk Pectin as a Carrier for Chronodelivery of Hydrocortisone Intended for Adrenal Insufficiency
por: Adi-Dako, Ofosua, et al.
Publicado: (2017)

SAT-391 Perioperative Glucocorticoid Therapy for Patients with Adrenal Insufficiency: Dosing Based on Hydrocortisone Pharmacokinetic Data
por: Rahhal, Marie-Noel, et al.
Publicado: (2019)

Nutritional Intervention in Cushing’s Disease: The Ketogenic Diet’s Effects on Metabolic Comorbidities and Adrenal Steroids
por: Guarnotta, Valentina, et al.
Publicado: (2023)

The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism
por: Choudhury, Sirazum, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ja4pqfbmrltcuu90inb82b6npc